Large tumor size predicted for worse local-regional control.
Local-regional control was not different in HNSCC patients treated definitively with concurrent chemoradiotherapy whether the chemotherapy was given intravenously or intra-arterially
Large tumor size predicted for poorer outcomes.
Intra-arterial cisplatin was associated with less nephrotoxicity, somewhat less ototoxicity, but more neurologic toxicity as compared to intravenous administration.
According to the discussant, Dr. K. Thomas Robbins, one possible reason for this negative result may be the fact that the Dutch group used more bilateral intraarterial infusions, as compared to what is generally done in the U.S. This bilateral infusion technique was used even when the primary HNSCC lesions extended only slightly across midline. As a result, there may have been some under-dosing of the tumor because of the divided chemotherapy administration.
Apr 16, 2010 - The U.S. cancer clinical trials system is in great need of an overhaul so that it can continue to support large-scale, multi-institutional clinical trials that result in gains in cancer treatment, according to a new report commissioned by the U.S. National Cancer Institute and conducted by the Institute of Medicine.